[8-K] Galectin Therapeutics Inc. Reports Material Event

Rhea-AI Filing Summary

Galectin Therapeutics Inc. furnished a Current Report on Form 8-K on August 14, 2025 announcing its results of operations and financial condition for the six months ended June 30, 2025 and providing a business update. The company incorporated by reference a press release dated August 14, 2025 filed as Exhibit 99.1 and included an interactive cover page XBRL as Exhibit 104. The filing notes that the press release contains forward-looking statements subject to risks described in Galectin's Annual Report for the year ended December 31, 2024. The information in Item 2.02 is furnished, not filed.

Positive

• The filing furnishes a press release
• The 8-K includes an interactive cover page XBRL as Exhibit 104, which supports structured data accessibility.

Negative

• The text of the 8-K does not include specific financial figures
• The press release contains forward-looking statements

Insights

Financial Analyst

TL;DR: Routine 8-K furnished press release with H1 2025 results; material implications depend on press release details.

This 8-K is a standard furnishing under Item 2.02 indicating Galectin has publicly announced its operating results and a business update for the six months ended June 30, 2025. The filing itself does not present financial tables or figures within the body, so investors must review Exhibit 99.1 to assess revenue, expense, cash position, and any changes to guidance or operations. The statement that forward-looking information is subject to risk factors in the 2024 Annual Report underscores routine disclosure controls and risk references. Overall, the filing signals disclosure compliance rather than a standalone material data release.

Corporate Governance Expert

TL;DR: Compliance-focused filing; shows timely disclosure but offers limited new data in the 8-K text.

The submission of an 8-K furnishing a press release and attaching Exhibit 99.1 and Exhibit 104 demonstrates the company is meeting SEC disclosure obligations. By expressly stating the press release contains forward-looking statements and referencing the 2024 Annual Report risk factors, management clarifies the legal framing of its statements. Because the report is furnished, not filed, the company limits incorporation risk for future registration statements. From a governance perspective this is a procedural, not transformative, disclosure.

08/14/2025 - 07:55 AM

false000113341600011334162025-08-142025-08-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  August 14, 2025

GALECTIN THERAPEUTICS INC.

 (Exact name of registrant as specified in its charter)

Nevada	001-31791	04-3562325
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240

NORCROSS, GA 30071

(Address of principal executive office) (zip code)

Registrant’s telephone number, including area code: (678) 620-3186

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock $0.001par value per share	GALT	The Nasdaq Stock Market

SECTION 2 – FINANCIAL INFORMATION

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the six months ended June 30, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 14, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1.

Except for the historical information contained in this report, the statements made by Galectin Therapeutics are forward-looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Galectin Therapeutics’ future financial performance could differ significantly from the expectations of management and from results expressed or implied in the Press Release. Forward-looking statements in the Press Release are subject to certain risks and uncertainties described in the Press Release. For further information on other risk factors, please refer to the “Risk Factors” contained in Galectin Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission, and its subsequent filings with the SEC.

The information in this Item 2.02 is being furnished, not filed, pursuant to Item 2.02 of Form 8-K. Accordingly, the information in Item 2.02 of this report, including the Press Release attached hereto as Exhibit 99.1, will not be incorporated by reference into any registration statement filed by Galectin under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release dated August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Galectin Therapeutics Inc.
Date: August 14, 2025	By:	/s/ Jack W. Callicutt
		Jack W. Callicutt
		Chief Financial Officer

- 3 -

FAQ

What did Galectin Therapeutics (GALT) file on August 14, 2025?

Galectin furnished a Form 8-K on August 14, 2025 announcing its results of operations and financial condition for the six months ended June 30, 2025 and providing a business update; the press release is attached as Exhibit 99.1.

Where can I find the press release referenced in the 8-K for GALT?

The press release dated August 14, 2025 is attached to the 8-K as Exhibit 99.1. The filing also includes an interactive cover page XBRL as Exhibit 104.

Does the 8-K include forward-looking statements?

Yes. The filing states the press release contains forward-looking statements and that those statements are subject to risks and uncertainties described in the company's 2024 Annual Report.

Are detailed financial numbers included directly in the 8-K?

No. The 8-K incorporates the press release by reference and does not present detailed financial figures within the body of the report; review Exhibit 99.1 for the results.

Who signed the 8-K for Galectin Therapeutics?

The report was signed on behalf of Galectin Therapeutics by Jack W. Callicutt, Chief Financial Officer on August 14, 2025.